11
Participants
Start Date
May 16, 2016
Primary Completion Date
May 31, 2019
Study Completion Date
May 31, 2019
Lenalidomide
Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
University of Florida Shands Cancer Center, Gainesville
Collaborators (1)
Celgene Corporation
INDUSTRY
University of Florida
OTHER